Neurotrack

Neurotrack is a digital health company that develops cognitive health solutions for testing and intervention. It has raised more than $50 million in funding from leading venture capital firms including Sozo Ventures, Marc Benioff, Khosla Ventures, Founders Fund, Social Capital, AME Cloud Partners and Rethink Impact, as well as strategic investments from Japanese insurance leaders, Dai-ichi Life and SOMPO Holdings. In 2019, it was the recipient of a SBIR fast-track grant worth up to $3.3 million from the National Institute on Aging, and the company’s scientific co-founders have raised over $7M in NIH grants to conduct research into its underlying technology. It has been named Best Health Company at SXSW, DEMO, and was a participant in the Rock Health accelerator.

Alzheimer’s, the most common form of dementia, affects more than 50 million people around the world today -- a number that’s expected to double every 20 years, reaching more than 130 million by 2050. It’s a complex disease that, for many, begins in mid-life and manifests in later years, and, at present, has no cure. Neurotrack is building the digital cognitive health platform of the future, giving people direct access to digital tools and technology to assess, monitor, and strengthen their brain health.

As a company rooted in science, Neurotrack regularly invests in studies, partnering with institutions that are leading the field in Alzheimer’s research, like Harvard, Stanford and Brown University, and works with a scientific advisory board comprised of leading academics and clinicians furthering Alzheimer’s and dementia research.